We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Nano-Laser Technology Could Eliminate Coronavirus from Bodies of COVID-19 Patients

By HospiMedica International staff writers
Posted on 22 Jul 2020
Print article
A patent pending treatment aims to use laser technology to eradicate the COVID-19 coronavirus by introducing one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., COVID-19 target antigens).

The technology has been developed by Halberd Corp. (Jackson Center, PA, USA) and will allow the virus to be seen and located, and allow for eradicating the fluorescent antibody-antigen complex by utilizing an energy burst from a nano-laser, with the removal of the debris through conventional mechanical filtering. The method entails the extracorporeal (outside the body) treatment of a patient's blood (for blood-borne diseases) or cerebrospinal fluid (CSF - for neurological diseases) consisting of a four-step process, including removal of bodily fluid from the patient; introduction of antibody-antigen complexing agent(s) to bind with the target antigen(s) (i.e., COVID-19 target antigens), eradicate the fluoresced antibody-antigen complex with a nano-laser and removal of the debris; and return of the cleansed bodily fluid to the patient.

This process is intended to be performed during a continuous-flow operation, similar to normal dialysis. By treating the blood or CSF outside of the patient, and using complexing agents which combine only with antigens associated with COVID-19, negative side-effects and reactions can be greatly reduced or eliminated.

“This process is intended to eliminate COVID-19 coronavirus, and its mutations from a patient's body. The use of a nano-laser and the associated complex computer controlled targeting system, should allow for a great flexibility in selecting and eliminating disease antigens, said Dr. Mitchell S. Felder, who invented the treatment.

“COVID-19 is a complex and virulent virus. We decided to pursue several alternatives of varying complexities in an attempt to address the complete elimination of the virus, and to develop an effective treatment protocol,” said William A. Hartman, Chairman, President & CEO of Halberd Corporation.

Related Links:
Halberd Corp.

Print article



view channel

Machine Learning Algorithm Identifies Deteriorating Patients in Hospital Who Need Intensive Care

Researchers have developed a machine learning algorithm that could significantly improve clinicians’ ability to identify hospitalized patients whose condition is deteriorating to the extent that they need... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.